(1:00 pm – 8:45 pm, CET Time Zone)

A – Opening session (1:00 pm – 2:10 pm)

Chairs: Stefan Anker, Germany, Andrew Coats, Australia & Mitja Lainscak, Slovenia

Stefan Anker, Germany

JCSM and its daughter journals
Stephan von Haehling, Germany

“Hippocrates” clinical science keynote lecture – Clinical classification of cancer cachexia
Vickie Baracos, Canada

“Prometheus” basic science keynote lecture – The different shades of wasting: organ contributions to cancer cachexia
Stephan Herzig, Germany

Panel Discussion

B – Clinical Session – Muscle wasting and cachexia in chronic illness (2:15 pm – 3:25 pm)
Chairs: Paola Costelli, Italy, Gustavo Duque, Australia & Giuseppe Rosano, UK

Sarcopenia – Highlights 2020
John Morley, USA

Muscle wasting and cachexia in stroke
Wolfram Doehner, Germany

Muscle wasting and function in rheumatoid arthritis
Hidenori Arai, Japan

 Wasting of the heart causing heart failure (in cancer and beyond)
Andrew Coats, Australia

Panel Discussion

Joint session SCWD – MASCC – EONS: Patient-centered cancer care to minimize anticancer treatment toxicity: a joint effort (3:30 pm – 4:25 pm)
Chairs: Stefan Anker, SCWD, Andreas Charalambous, EONS & Edigio Del Fabbro, MASCC

The power of nursing interventions in the comprehensive management of treatment-induced side-effects
Andreas Charalambous, Cyprus

Rehabilitation before, during, in-between, and after anticancer treatment in curative and non-curative intent: How?!
Andrea L. Cheville, USA

Cancer-disease and cancer-treatment related fatigue: multimodal evidenced-based transprofessional management
Florian Strasser, Switzerland

Evidenced-based and personalized dosing of exercise in patients with or after cancer
Joachim Wiskemann, Germany

Panel Discussion

C – Basic session –Cachexia and wasting in disorders of the skeletal muscle: from molecular mechanisms to treatment perspectives (4:30 pm – 5:40 pm)

Chairs: Jason Doles, USA, Hanns Lochmüller, Canada & Jens Schmidt, Germany

The metabolome and proteome of blood in patients with muscular dystrophy
Pietro Spitali, The Netherlands

Gene therapy for muscular dystrophy: Are we there yet?
Kevin M. Flanigan, USA

 Motor neuron disease models
Jochen Weishaupt, Germany

 Engineering human iPS cells for muscle disease modelling and therapy development
Francesco Saverio Tedesco, UK

Panel Discussion

D – Clinical session – Thoracic CT imaging and other methods to assess muscle wasting in clinical and research sessions (4:30 pm – 5:40 pm)

Chairs: Jeffrey Crawford, USA, Steven Heymsfield, USA & Annemie Schols, The Netherlands

L3 and T4 landmarks predict mortality and key measures of function
Asmita Mishra, USA

CT-based body composition measures in chronic lung disease and lung transplantation
Dmitry Rozenberg, Canada

Use of thoracic CT imaging in clinical trials to assess muscle mass – the record so far
Vickie Baracos, Canada

D3creatine dilution measured muscle mass in comparison to DXA lean mass for risk prediction in older men
Bill Evans, USA

Panel Discussion

E – Basic session – Fat and inflammation in cachexia (5:45 pm – 6:55 pm)

Chairs: Volker Adams, Germany, Denis Guttridge, USA & Maurilio Sampaolesi, Belgium

Inflammation and muscle catabolism in patients with cachexia
T. Alp Ikizler, USA

Organoid as a model to study adipose tissue remodeling in cancer cachexia
Miguel L. Batista Jr, USA

Tumor-adipose-muscle crosstalk in cancer cachexia
Teresa Zimmers, USA

The lipids-endotoxin interaction and inflammation in chronic illness
Stephan von Haehling, Germany

Panel Discussion

F – Clinical session – Cancer cachexia and muscle dysfunction (5:45 pm – 6:55 pm)

Chairs: Andrea Bonetto, USA & Jeffrey Crawford, USA

Mechanisms of doxorubicin toxicity in cardiac and skeletal muscle
Ashley Smuder, USA

Advancing biomarkers in pancreatic cancer cachexia
Erin Talbert, USA

 Role of the BMP pathway in cancer cachexia
Roberta Sartori, Italy

 Mechanisms of chemotherapy-induced muscle wasting in cancer cachexia
Kate Murphy, Australia

Panel Discussion

Abstract session 1 – Cachexia – mechanisms, animal models I (7:00 pm – 7:50 pm)

Chairs: Jochen Springer, Germany & Gustavo Nader, USA

1-01 – Rehabilitating cachexia – development and functional characterization of a novel longitudinal and translational model of cancer-associated cachexia
Ishan Roy, USA

1-02 – Alterations in Mitochondrial Turnover during the Development of Cancer Cachexia in Tumor-Bearing Female Mice
Seongkyun Lim, USA

1-03 – Alterations in Extracellular Matrix Remodeling During Early Stages of Cancer Cachexia in Tumor-bearing Female Mice
Francielly Morena da Silva, USA

1-04 – Quercetin administration attenuates cancer-related cachexia and increases cancer-related survival and in C57BL/6 mice bearing syngeneic Cutaneous melanoma model
Alfredo de Paula, Brazil

1-05 – Molecular and physiologic characterization of a novel murine model of metastatic head and neck cancer cachexia
Brennan Olson, USA

1-06 – Characterizing biological mechanisms of muscle wasting in a clinically relevant model of colorectal cancer and sequential chemotherapy treatment
Gauhar Ali, Canada

1-07 – The role of adipose tissue breakdown in the acute phase of sepsis: a comparison of interorgan fluxes of amino acids and glycerol in a Pseudomonas aeruginosa induced septic pig model
Ryan Morse, USA

1-08 – Chronic cachexia is dependent on sustained IL-1R signaling during parasite infection
Sarah Ewald, USA

1-09 – GDF15 neutralization does not impact anorexia or survival in the LPS acute inflammation mouse model
Zhidan Wu, USA

1-10 – Metabolomic biomarker candidates for skeletal muscle loss in the collagen-induced arthritis (CIA) model
Marianne Oliveira, Brazil


Abstract session 2 – Nutrition & Appetite (7:00 pm – 7:50 pm)

Chairs: Alessandro Laviano, Italy & Nicolaas Deutz, USA

6-01 – Nutrition status and sarcopenia in discharged hospital patients in Iceland
Alfons Ramel, Iceland

6-02 – Weight loss, malnutrition and physical function in community dwelling old adults in Iceland
Alfons Ramel, Iceland

6-03 – Nutritional signature and body composition adaptations at high-altitude: Western trekkers vs Eastern porters
Danilo Bondi, Italy

6-04 – Association between changes in nutrients intake and changes in muscle strength and physical performance in the SarcoPhAge cohort
Laetitia Lengelé, Belgium

6-05 – Resting Energy Expenditure changes after 2 weeks of Very Low-Calorie Diet are associated with baseline production rates of specific amino acids
Raven McNew, USA

6-06 – Impairments in small intestinal function are associated with reduced muscle quality in a group of Congestive Heart Failure and healthy participants
Sarah K. Kirschner, USA

6-07 – Elevated meal-induced anabolic response after four weeks of ω3 fatty acid supplementation in Chronic Obstructive Pulmonary Disease (COPD)
Marielle Engelen, USA

6-09 – Presence of cachexia and impaired appetite in hospitalized elderly cancer patients
Valdete Guandalini, Brazil

6-10 – Hospitalized cancer patients with high neutrophil to lymphocytes ratio had lower calf circumference and increased risk of malnutrition
Gustavo Pimentel, Brazil

Abstract session 3 – Muscle wasting & sarcopenia – mechanisms I (7:55 pm – 8:45 pm)

Chairs: Scott Brakenridge, USA & Jason Doles, USA

5-01 – Muscle Mass as a Potential Marker for Chronic Maltreatment in the Pediatric Non-Accidental Trauma Patient
Gregory Metzger, USA

5-02 – Evaluation of the nutrients intake in a group of Jordanian elderly people with sarcopenia syndrome in Amman
Sara Majali, Jordan

5-03 – Association of muscle mass reduction and hand grip strength reduction with health-related quality of life of patients with colorectal cancer
Mariana Barbosa, Brazil

5-04 – Ovarian cancer ascites induces skeletal muscle wasting in vitro
Sander Rensen, The Netherlands

5-05 – Postoperative loss of skeletal muscle mass is prognostic of poor survival after gastric cancer surgery
Feng Zhou, China

5-06 – Respiratory function in subjects recovered from COVID-19 with sarcopenia
Carlos Sánchez-Moreno, Mexico

5-07 – Impact of prolonged sepsis on biomechanical and structural myofibrillar properties
Chloë Goossens, Belgium

5-08 – Synergistic short-term and long-term effects of TGF-β1 and 3 on collagen production in differentiating myoblasts
Andi Shi

5-09 – Lack of TGF-β type I receptors Tgfbr1 and Acvr1b synergistically stimulate myofibre hypertrophy and accelerates early muscle regeneration
Andi Shi

5-10 – Gender differences in muscle-ageing: a cross-sectional study
Jelle de Jong, The Netherlands

5-12 – Quorum Sensing Molecules: potential theranostics in muscle wasting
Anton De Spiegeleer, Belgium

Abstract session 4 – Diagnosis of sarcopenia I (7:55 pm – 8:45 pm)

Chairs: Josep Argiles, Spain & Jürgen Bauer, Germany

4-02 – The validity of SARC-F on screening sarcopenia defined by AWGS 2019 in hospitalized older adults
Keisuke Maeda, Japan

4-03 – Comparison of diagnostic performance of SARC-F and its two modified versions (SARC-CalF and SARC-F+EBM) in community-dwelling older adults from Poland using two sets of diagnostic criteria of sarcopenia developed by The European Working Group on Sarcopenia in Older People (EWGSOP1 and EWGSOP2)
Roma Krzymińska-Siemaszko, Poland

4-04 – Clinimetric properties of the newly developed short form Sarcopenia Quality of Life (SF-SarQoL®) questionnaire
Anton Geerinck, Belgium

4-05 – Consequence of SARC-CalF on SARC-F’s screening sensitivity and specificity among community-dwelling older adults: a systematic review
Rômulo Roosevelt Silva Filho

4-06 -Establishing a hierarchy of importance for different aspects of quality of life in sarcopenia from a patient perspective, a best-worst scaling survey
Anton Geerinck, Belgium

4-07 – Screening for the risk of sarcopenia in hospitalized individuals
Maria Spexoto, Brazil

4-09 – The joint association of frailty and sarcopenia with incidence health outcomes: Findings from the UK Biobank prospective cohort study
Fanny Petermann-Rocha, UK

4-10 – GripBMI – a fast and simple sarcopenia screening tool in post acute inpatient rehabilitation
Irina Churilov, Australia

4-11 – Development of appendicular muscle mass estimating formulas for older adults considering paralysis
Junko Ueshima, Japan

4-12 – Body composition of long-living patients with coronary artery disease
Svetlana Topolyanskaya, Russia


(1:00 pm – 8:45 pm, CET Time Zone)

Abstract session 5 – Cachexia – mechanisms, animal models II (1:00 pm – 2:10 pm)

Chairs: Maurilio Sampaolesi, Belgium & Didier Attaix, France

1-11 – Expression and role of microRNAs associated with inflammation in cancer cachexia
Joana Santos, Portugal

1-12 – Distinct tissue-specific gene regulation and potential inter-organ communication in a mouse model of cancer cachexia
Ji-Won Heo (Kim), Korea

1-13 – Multi-compartment metabolomics and metagenomics reveal new metabolic targets in cancer cachexia
Sarah Pötgens, Belgium

1-14 – Characterization of a novel, mouse orthotopic lung cancer model to study lung cancer cachexia
Wouter van de Worp, The Netherlands

1-15 – Nutraceutical role of leucine in the protein imbalance of the cachectic heart
Gabriela de Matuoka e Chiocchetti, Brazil

1-16 – Relationship between leucine and cancer in the process of sarcopenia and cachexia in ageing Walker 256 tumour-bearing rats
Leisa Lopes-Aguiar, Brazil

1-17 – A nutritional supplementation with leucine improved walking, behaviour and strength tests of cachectic Walker 256 tumour-bearing Wistar rats
Maria Cristina Cintra Gomes-Marcondes, Brazil

1-18 – Changes in browning of white adipose tissue in cancer cachexia
Alessio Molfino Italy

1-20 – Resolvin E1 attenuates endotoxin induced muscle atrophy in human derived muscle cells
Luke Baker, UK

1-21 – C2C12 incubated with cancer conditioned medium as a model for functional mitochondrial measurements
Miranda van der Ende, The Netherlands

1-22 – Phosphorylation of dystrophin S3059 protects against C2C12 myotube atrophy
Kristy Swiderski, Australia

1-23 – The role of 11β-HSD1 in glucocorticoid signalling and muscle atrophy in a model of acute exacerbation of COPD
Justine Webster, The Netherlands

Abstract session 6 – Cancer cachexia (1:00 pm – 2:10 pm)

Chairs: Paola Costelli, Italy & Mauricio Berriel Diaz, Germany

3-01 – Low cholinesterase levels at diagnosis of pancreatic cancer are associated with cachexia and pancreatic cancer prognosis
Seiko Miura, Japan

3-02 – Metabolic reprogramming drives pancreatic cancer-associated wasting
Katherine R. Pelz, USA

3-03 – The human pancreatic tumor organoid secretome suppresses macrophage mitochondrial respiration without affecting macrophage function
Min Deng, The Netherlands

3-04 – Prevalence and severity of cancer cachexia by BMI-Weight Loss (WL) Grades in advanced stage gastrointestinal and lung cancers: a population–based study
Lisa Martin, Canada

3-05 – Inflammation-induced cholestasis in cancer cachexia
Morgane Thibaut, Belgium

3-06 – Gray and white matter morphology in cachectic colorectal cancer patients: A voxel-based morphometry MRI study
Estefania Simoes, Brazil

3-07 – The Impact of Circulating Tumor Cells on Cancer Cachexia in Small-Cell Lung Cancer
Tateaki Naito, Japan

3-08 – SARC-F Questionnaire score is Associated with Mortality of Cancer Patients Receiving Palliative Care
Naoharu Mori, Japan

3-09 – Growth differentiation factor 11 (GDF11) is not a key regulator of cancer cachexia
Brianna LaCarubba, USA

3-10 – Oxytocin, the neurohypophyseal hormone has an anti-cachectic potential
Alexandra Benoni, Italy

3-11 – Role of miR-223-3p in cancer cachexia
Lorena Garcia Castillo, Italy

3-12 – RNA bio-profiling studies from human skeletal muscle biopsies in Cancer Cachexia research: an update
Bhumi Bhatt, Canada

3-13 – C-reactive protein and its relationship with pain in advanced cancer cachexia
Koji Amano, Japan

3-14 – Assessment of Nutritional Status on hospital admission, a Portuguese oncology center study
Carolina Trabulo, Portugal

3-15 – Tumor-derived PTHrP in patients with cachexia
Tanja Krauss, Germany

3-16 – Circulating lipids are defining features of murine and human cancer cachexia
Julia Zuber, Germany

G – Basic session – Novel research finding in muscle wasting disorders and cachexia (2:15 pm – 3:25 pm)

Chairs: Didier Attaix, France, Xiaonan Wang, USA & David Waning, USA

Novel players that control muscle mass in disease
Marco Sandri, Italy

The role of glucagon in tumor-induced muscle wasting of the insects and mammals
Wei Roc Song, China

Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function
Antonio Zorzano, Spain

Impaired ribosome biogenesis as an underlying cause of muscle wasting
Gustavo A. Nader, USA

Panel Discussion

H – Clinical session – Hot topics in skeletal muscle plasticity and muscle wasting (2:15 pm – 3:25 pm)

Chairs: Scott Brakenridge, USA, Sven Geißler, Germany & John Morley, USA

Muscle stem cell mechanotransduction and TGF-beta signaling in muscle regeneration and fibrosis
Richard Jaspers, The Netherlands

Is muscle fibre size constrained by oxidative capacity?
Hans Degens, UK

Therapeutic potential of slow muscle programming for muscle diseases
Gordon Lynch, Australia

Cell therapy strategies for skeletal muscle injury
Tobias Winkler, Germany

Panel Discussion


Update on clinical research on sarcopenia (3:30 pm – 4:25 pm)
Supported by an unrestricted educational grant from Biophytis

Chair: Bruno Vellas, France

Current status of clinical research targeting Sarcopenia
Roger Fielding, USA

SARA program: the use of BIO101, a MAS receptor agonist, for the treatment of sarcopenia
Cendrine Tourette, France

Panel Discussion
Bruno Vellas, France, Roger Fielding, USA, Waly Dioh, France &Sam Agus, USA


I – Basic session – Body weight control in humans (4:30 pm – 5:40 pm)
Chairs: Swarnali Acharyya, USA, Josep Argiles, Spain & Aminah Jatoi, USA

How to screen for cachexia in humans
Richard Skipworth, UK

Cross-talk between bone and muscle in metastatic cancer
Theresa Guise, USA

Connecting diet, metabolism, and tumor growth in human cachectic patients with cancer
Marcus Goncalves, USA

GDF-15 is a key regulator in cancer cachexia
Bei Zhang, USA

Panel Discussion

J – Clinical session – Automated body composition analysis: using efficiently biomarkers and CT scans (4:30 pm – 5:40 pm)

Chairs: Jerome Feige, Switzerland, Andrea Maier, Australia & Francesco Landi, Italy

Biomarkers of physical frailty and sarcopenia – BIOSPHERE study
Emanuele Marzetti, Italy

Biomarkers to assess skeletal muscle loss and malnutrition
Adrian Slee, UK

Clinical applications of automated CT scans
Bette Caan, USA

Looking to the future of automated analysis
Mirza Faisal Beg, Canada

Panel Discussion

K – Basic session – Pharmacological reverse of cancer cachexia (5:45 pm – 6:55 pm)

Chairs: James Carson, USA, David Glass, USA & Teresa Zimmers, USA

Lipocalin-2 regulates appetite and neurocognitive decline during cancer cachexia
Daniel Marks, USA

A selective inhibitor of p38β MAPK abrogates muscle wasting and prolongs survival of tumor-bearing mice
Yi-Ping Li, USA

GDF15 neutralization reverses cancer cachexia and restores physical performance
Zhidan Wu, USA

Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting
Stef Levolger, The Netherlands

Panel Discussion

L – Clinical session – Sarcopenia and cachexia in renal disease (5:45 pm – 6:55 pm)
Chairs: Luigi Ferrucci, USA, Hidetaka Wakabayashi, Japan & Stephan von Haehling, Germany

The role of IL-1 in experimental CKD cachexia: Potential for novel therapy
Robert Mak, USA

Kidney cachexia or protein energy wasting?
Kamyar Kalantar-Zadeh, USA

Clinical phenotype of cachexia in kidney disease
Joanne Reid, UK

Sarcopenia in chronic kidney disease
Cynthia Delgado, USA

Panel Discussion


Statistical seminar “Analysis of observational studies” (7:00 pm – 7:50 pm)
Coordination: Jennifer Le Rademacher, USA & Ruta Brazauskas, USA

Although clinical trials are the gold standard for evaluating experimental treatments, in settings where clinical trials may not be feasible or ethical, observational studies are the next best option. Due to the observational nature of this type of studies, there are potential selection bias or confounding factors that need to be accounted for when assessing treatment effect or comparing groups of patients.  In this seminar, we will introduce various types of observational studies, common pitfalls, and common analysis approaches for observational studies. Specifically, we will focus on the pros and cons of two analysis approaches: regression modeling versus matched pairs (clusters) comparison. We will use real data examples to illustrate these methods.

Abstract session 7 – Physical activity & Training (7:00 pm – 7:50 pm)

Chairs: Fabio Penna, Italy & Volker Adams, Germany

7-01 – Country- and gender-specific cut points for low allometrically adjusted grip strength from 13,235 older adults of low- and middle-income countries
Pedro Abdalla, Brazil

7-02 – Influence of a movement program on mobility in very elderly individuals – quasi-experimental study
Ana Gonçalves, Portugal

7-03 – Integrating a preventive care path into daily life of older adults with mobility disability risk: introducing a predictive model to the exercise response
Leo Delaire, France

7-04 – Does the presence of abdominal obesity impact physical-functional parameters in community-dwelling elderly women?
Patricia Batista, Brazil

7-05 – Muscle architectural changes in Response to Eight-Week Neuromuscular Electrical Stimulation Training in Healthy Older People
Danilo Bondi, Italy

7-06 – Six minute walk test performance is related to oxygen use and production of specific muscle related amino acids but not muscle mass
Clayton Cruthirds, USA

7-07 – Assessing the impact of inpatient rehabilitation on functional recovery from cachexia/muscle wasting in cancer – a combinatorial approach
Ishan Roy, USA

7-08 – Interest and faisability of intra-dialytic resistance work sessions in the fight against dynapenia in elderly, high comorbidity patients
Damien Paris, France


Abstract session 9 – Therapeutic development (clinical) + Therapeutic development (pre-clinical) I (7:55 pm – 8:45 pm)

Chairs: Jose Garcia, USA & Mitja Lainscak, Slovenia

8-01 – SARA-OBS study: natural progression of sarcopenia and sarcopenic obesity in older adults
Cendrine Tourette, France

8-02 – Changes in Plasma and Urinary Metabolites After Elamipretide in Barth Syndrome Patients: Analyses from the TAZPOWER study
Hilary Vernon, USA

8-03 – Investigating a multimodal nutrition and exercise intervention for the treatment of cachexia in patients with Lung and GI cancers: a randomized clinical trial in Progress
Richard Dunne, USA

8-04 – Serum creatinine to Cystatin C ratio as a potential muscle mass surrogate unfolds racial differences in kidney function assessments and outcomes among Black and non-Black US Veterans
Elani Streja, USA

8-05 – Modulation of AMPK activity and protein turnover signaling in disused rat soleus muscle
Timur Mirzoev, Russia

8-06 – Metformin administration mitigates disuse-induced rat soleus muscle wasting
Timur Mirzoev, Russia

8-07 – Ageing-related Neuromuscular Junction Degeneration in Sarcopenia is Attenuated by Vibration Treatment
Zhengyuan Bao, China

8-08 – Voluntary wheel running with and without follistatin overexpression improves neuromuscular junction transmission but not motor unit loss in aging C57BL/6J mice
Deepti Chugh, USA

Abstract session 10 – Muscle wasting & sarcopenia – mechanisms II (7:55 pm – 8:45 pm)

Chairs: David Waning, USA & Srinivasan Dasarathy, USA

5-13 – Circulating levels of FGF-21 and muscle-related miRNA in cancer patients
Alessio Molfino, Italy

5-14 – Extracellular vesicle-derived microRNAs enhance stem cell-based regeneration of skeletal muscle in muscle wasting conditions
Laura Yedigaryan, Belgium

5-15 – Regulation of TGF-β signaling by SPSB1 plays a role in inflammation-induced muscle atrophy
Yi Li, Germany

5-16 – Skeletal muscle fibre-type and oxygen transport  limitations in obese-HFpEF
Ever Espino-Gonzalez, UK

5-18 – Early Differential Responses by Sex to Hindlimb-Unloading Induced Muscle Atrophy
William Deaver, USA

5-19 – Acetyltransferases p300 and CBP are not required for normal skeletal muscle regeneration after injury
Alexandra Stanley, USA

5-20 – Transcriptomic analysis of the obesity effects in aged-sarcopenic mice
Landen Saling, USA

5-21 – Optimized Grip Testing and Comparison with In Vivo Muscle Contractility in Dynapenic Aged Mice
Gregory Owendoff, USA

5-22 – Electrical impedance myography correlates with muscle mass and neuromuscular deficits during aging: a potential instrument for sarcopenia?
Carlos J. Padilla, USA

5-23 – Co-application of Oral Magnesium Supplementation and Low-Magnitude, High-Frequency Vibration Treatment Attenuates Sarcopenia via PI3k/Akt/mTOR Pathway
Can Cui, China

5-24 – Follistatin-induced Muscle Hypertrophy in Aged mice Improves Neuromuscular Junction Form and Function
Chitra Iyer, USA


(2:15 pm – 8:45 pm, CET Time Zone)

M – Basic session – Fat tissue and lipid metabolism (2:15 pm – 3:25 pm)

Chairs: Roger Fielding, USA, Stephan Herzig, Germany & Jochen Springer, Germany

Lipid metabolism in cancer cachexia
Maria Rohm, Germany

Adipose tissue remodeling in human cancer cachexia
Marilia Seelaender, Brazil

Fat tissues and prognosis in human chronic illness
Markus Anker, Germany

Tumor-derived mediators of cancer cachexia
Mauricio Berriel Diaz, Germany

Panel Discussion

N – Difference in diagnostic criteria for sarcopenia and sarcopenic obesity (2:15 pm – 3:25 pm)

Chairs: Olivier Bezy, USA, Marc Bonnefoy, France & Bill Evans, USA 

Cachexia as a global problem – data from different continents
Mitja Lainscak, Slovenia

Obesity paradox for survival: Update 2020
Giuseppe Rosano, United Kingdom

Diagnostic criteria for sarcopenia and sarcopenic obesity in Asia
Masaaki Konishi, Japan

Diagnostic criteria for sarcopenia and sarcopenic obesity in Europe
Juergen Bauer, Germany

Panel Discussion

Neuroendocrine and Autonomic Dysfunction in Cancer Cachexia (3:30 pm – 4:25 pm)
Supported by an unrestricted educational grant from Pfizer

Chairs: Stefan Anker, Germany & Andrew Coats, Australia

Neuroendocrine and Autonomic Dysfunction in Cancer Cachexia
Daniel Marks, USA

Panel discussion

O – Late breaking research/trials (4:30 pm – 5:40 pm)

Chairs: Stefan Anker, Germany, Andrew Coats, Australia, Jeffrey Crawford, USA, Jose Garcia, USA, Aminah Jatoi, USA, Alessandro Laviano, Italy & Frank Misselwitz, Germany

s-oxprenolol for amyotrophic lateral sclerosis (ALS)
Jochen Springer, Germany

SARM for COPD cachexia
Bill Evans, USA

Trial in progress: Anamorelin phase 3 studies in patients with NSCLC and cachexia
Edwin de Wit (Helsinn), Switzerland

MMPOWER-3 Phase 3 Clinical Trial Results: Elamipretide improved six-minute walk test in individuals with mtDNA replisome disorders
Michelangelo Mancuso, Italy

Panel Discussion

P – Skeletal muscle as a metabolic organ and the impact of exercise (5:45 pm – 6:55 pm)

Chairs: Nicolaas Deutz, USA, Mathias Plauth, Germany & Fabio Penna, Italy

Metabolic and molecular integration in regulation of skeletal muscle mass
Srinivasan Dasarathy, USA

Exercise in cancer patients
Jesper Christensen, Denmark

Nutrition and appetite stimulants: therapeutic or palliative drugs?
Maurizio Muscaritoli, Italy

Age-related gene expression signature
David Glass, USA

Panel Discussion

Abstract session 11 – Diagnosis of sarcopenia II (7:00 pm – 7:50 pm)

Chairs: Marc Bonnefoy, France & Francesco Landi, Italy

4-25 – Sarcopenia and health-related quality of life in colorectal cancer
Mariana Barbosa, Brazil

4-26 – Sarcopenia in cancer palliative care: results of a prospective study
Jonas Dubu, France

4-27 – Adipose tissue radiodensity: characteristics and relation to survival in a population-based cancer cohort and literature review
Md Monirujjaman, Canada

4-28 – Differences in the prevalence of low muscle mass in cancer patients based on different cut-off values
Jona Van den Broeck, Belgium

4-29 – Sarcopenia predicts dose-limiting toxicity in pancreatic cancer treated with nab-paclitaxel and gemcitabine
Susie Youn, Canada

4-30 – Predicting chemotherapy toxicity in older patients with cancer based on variables related to sarcopenia. ONCOSARCO Project
MJ Molina-Garrido, Spain

4-31 – Who is most at risk of severe chemotherapy toxicity, sarcopenic or frail elderly patients? The ONCOSARCO Project
MJ Molina-Garrido, Spain

4-32 – Could aortic calcification reveal the body composition inflammatory changes?
Ioanna Drami, UK

4-33 – Bioelectrical impedance analysis-derived phase angle as a marker of Computerized Tomography-muscle mass abnormalities and muscle function in patients with cancer
Nilian Carla Souza, Brazil

4-34 – Does sarcopenia equate to frailty: comparing subjects EWGSOP sarcopenic status and their Clinical Frailty Scale?
Angela G. Juby, Canada

4-35 – Older men with sarcopenia have rapid progression of abdominal aortic calcification – the prospective MINOS study
Pawel Szulc, France

4-36 – Sirtuin1 function is critical for preventing skeletal muscle wasting in cerebral ischemic stroke
Junaith S. Mohamed, USA

Abstract session 12 – Therapeutic development (pre-clinical) II (7:00 pm – 7:50 pm)

Chairs: James Carson, USA & Roger Fielding, USA

9-01 – Growth differentiation factor 15 (GDF-15) blockade restores muscle function and physical performance in a mouse model of cancer-induced cachexia
Ja Young Kim-Muller, USA

9-02 – Growth differentiation factor 15 (GDF-15) inhibition attenuates platinum-based chemotherapy-induced emesis, anorexia and weight loss and increases survival
Bei Zhang, USA

9-03 – Folfox Chemotherapy induces Chronic Metabolic Dysfunction and Fatigue in Mice
Brittany Counts, USA

9-04 – Dietary EPA and DHA restore altered lipid metabolism pathways associated with chemotherapy-induced myosteatosis in a preclinical model of colorectal cancer: a skeletal muscle transcriptomic analysis
Peter Isesele, Canada

9-05 – Protection Against Doxorubicin-Induced Cardiac Dysfunction is Not Maintained Following Prolonged Autophagy Inhibition
Ryan N. Montalvo, USA

9-06 – Alterations in hepatic fatty acids in chemotherapy-associated steatohepatitis (CASH) reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer
Md Monirujjaman, Canada

9-07 – Atenolol improves skeletal muscle architecture and inhibits immobilization-induced muscle atrophy
Kushwaha Sapana, India


Abstract session 8 – Diagnosis of sarcopenia III (7:55 pm – 8:45 pm)

Chairs: Josep Argiles, Spain & Jürgen Bauer, Germany

4-13 – Sarcopenia detection using a handheld dynamometer in fracture Neck of Femur patients presenting to a District General Hospital
Sanjay Suman, UK

4-14 – Longitudinal association of severe sarcopenia and mild cognitive impairment among older Mexican adults
Rosa Palazuelos, Mexico

4-15 – Sarcopenia and circulating leptin levels in community-dwelling older Chileans
Cecilia Albala, Chile

4-16 – Investigation in to the relationship between markers of nutritional status, sarcopenia and frailty, and clinical outcomes in older hospital patients
Adriana Salame, UK

4-17 -Associations between sarcopenia, osteoporosis and frailty in community dwelling older adults: findings from the Hertfordshire Cohort Study (HCS)
Faidra Laskou, UK

4-18 – Sarcopenia is associated with mortality in adults: A systematic review and meta-analysis
A. B. Maier, The Netherlands

4-19 – Muscle assessment by echografy in a cohort of older adults and its utility in sarcopenia diagnosis
Marta Neira Alvarez, Spain

4-20 – Cut-points for adverse muscle composition predicts all-cause mortality
Jennifer Linge, Sweden

4-21 – Sarcopenia and cardiovascular risk in patients with chronic kidney disease on peritoneal dialysis
Sheila Borges, Brazil

4-22 – Sarcopenia and cardiovascular risk in patients with chronic kidney disease on hemodialysis: a cross-sectional study
Sheila Borges, Brazil

4-23 – Sarcopenia, chronic kidney disease and the risk of mortality and end stage renal disease: findings from 428,331 individuals in the UK Biobank
Thomas Wilkinson, UK

4-24 – Sarcopenia in patients with bladder or kidney cancer
Patrícia Fonseca dos Reis, Brazil